Court Removes Obstacle To Teva’s Cholesterol Drug

Law360, New York (April 20, 2006, 12:00 AM EDT) -- Clearing the way for Teva Pharmaceutical Industries Ltd.’s intended launch, a U.S. court has lifted an order that had threatened to delay final approval of the Israeli drug maker’s generic version of the blockbuster cholesterol drug Pravachol.

The company announced the news this week, adding that it expected to receive final approval for generic pravastatin on Thursday, the date that Bristol-Myers Squibb’s original patent was scheduled to expire.

The preliminary injunction’s removal came in the wake of the U.S. District Court for the District of Columbia...
To view the full article, register now.